Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 12/20 | 0.51 |
| ▸ | NPC1 | O15118 | 10/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27333980 | 0.84 | GLS (0.52) | MAPTRAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL27323009 | 0.84 | MAPK1 (0.62) | MAPTRAB9ANPC1SMN1; SMN2POLB | |
| SCHEMBL6841098 | 0.83 | MAPT (0.62) | MAPTRAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL24169890 | 0.83 | PI4KB (0.46) | PI4KB | |
| SCHEMBL3777740 | 0.83 | PI4KB (0.46) | PI4KB | |
| SCHEMBL1744171 | 0.83 | PI4KB (0.46) | RAB9ANPC1PI4KB | |
| SCHEMBL28226290 | 0.83 | PI4KB (0.46) | PI4KB | |
| SCHEMBL27320005 | 0.82 | HTT (0.60) | MAPTRAB9ANPC1POLBGAA | |
| SCHEMBL8918968 | 0.81 | HTT (0.50) | MAPTRAB9ANPC1PI4KBSMN1; SMN2 | |
| SCHEMBL27321055 | 0.81 | GAA (0.49) | MAPTRAB9ANPC1PI4KBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034105-A1 | Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors | THE FIRST AFFILIATED HOSPITAL OF XI'AN JIAOTONG UNIVERSITY (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-3952870-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZENSHINE PHARMACEUTICALS CO LTD (CN) | 2025-09-24 | — | — | EP | disclosed |
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| CN-118084801-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084800-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112312913-B | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2023-11-07 | — | — | US | disclosed |
| WO-2023165551-A1 | SIX-MEMBERED AROMATIC RING-PYRROLIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-09-07 | — | — | WO | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-08 | — | — | US | disclosed |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-05-08 | — | — | US | disclosed |
| EP-1912983-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals, Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2008042353-A1 | POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042353-A1 | POTENT AND HIGHLY SELECTIVE HETEROAROMATIC INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2007021982-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021982-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1670478-A2 | HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107369-A1 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-05-19 | — | — | US | disclosed |
| WO-2005026111-A2 | HETEROAROMATIC SELECTIVE INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE | NORTHWESTERN UNIVERSITY (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107369-A1 | Heteroaromatic selective inhibitors of neuronal nitric oxide synthase | NOS1, NOS2, NOS3 | MAPT 175/4885RAB9A 2584/4885NPC1 404/4885 |
| US-20260034105-A1 | Generative AI-Assisted Identification of Novel PI3K-alpha Inhibitors | PIK3R1, PIK3R4, PIK3R2 | MAPT 4207/4885RAB9A 1508/4885NPC1 134/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | MAPT 22/4885RAB9A 2129/4885NPC1 72/4885 |
| US-20230227446-A9 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KB, PI4KA, PIK3CD | MAPT 3807/4885RAB9A 997/4885NPC1 1535/4885 |
| US-20080108814-A1 | Potent and highly selective heteroaromatic inhibitors of neuronal nitric oxide synthase | NOS1, NOS2, NOS3 | MAPT 129/4885RAB9A 2890/4885NPC1 462/4885 |
| US-11807621-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | MAPT 3652/4885RAB9A 1828/4885NPC1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.